UNSPSC 51361804: Fepitrizol

This classification denotes a sedative and hypnotic with the molecular formula C15H14N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M9C5T4Q638, chemically known as 1-methyl-3-(3-pyridyl)-5-(2-hydroxymethylphenyl)-1h-1,2,4-triazole but generally known as fepitrizol, which bears US NIH Compound Identifier 68702. European Medicines Agency schedules Fepitrizol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07605MIG.

UNSPSC 51361804 Fepitrizol is a Commodity code that does not align with the recent state and local procurement activity tagged under it. The posted opportunities—naloxone procurement, therapeutic pharmacy initiatives, and generic multi-source pharmaceutical supply—fall outside the scope of fepitrizol, an azole antifungal agent used in veterinary and agricultural applications. The code shows no relevant recent activity in the state and local government contracting market.

The three most recent opportunities posted under this code address pharmaceutical supply, emergency medical response consumables, and pharmacy benefit program design rather than fepitrizol or related antifungal products. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking naloxone and safe drug deactivation systems on a competitive bid basis; the Texas Health and Human Services Commission posted an RFI in April 2026 on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 deadline. The mismatch between the code's nominal pharmaceutical classification and the actual work being bought suggests either a tagging error in the state and local procurement systems or that fepitrizol itself does not drive meaningful procurement volume in this market. Business development professionals should verify the code classification with issuing bodies or consider repositioning toward the pharmaceutical supply and health services codes where recent activity is concentrated.